From Yahoo Finance: 2025-05-21 11:17:00

Altimmune, Inc. (ALT) is considered one of the 13 Best Multibagger Stocks to Invest in Now, with Wall Street analysts predicting a 288% upside potential over the next year. ALT is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic, and liver diseases, with pemvidutide as its lead product/candidate.

The mechanism of action for pemvidutide involves activating GLP-1 and glucagon receptors to mimic the effects of diet and exercise on weight loss. Clinical trials involving over 500 subjects have shown a favorable safety profile and significant clinical benefits, leading Altimmune to explore additional indications beyond obesity and MASH. ALT’s first quarterly earnings for 2025 exceeded forecasts at $5,000, with plans to support pemvidutide’s development through a credit facility with Hercules Capital.

Despite concerns about cash holdings, Altimmune, Inc. secured a $100 million credit facility to bolster its balance sheet and support pemvidutide’s development. Analysts project an average twelve-month trading price of $22.38 for ALT, representing a 288.54% upside potential. While ALT ranks 10th on the list of Best Multibagger Stocks, other AI stocks may offer greater promise with limited downside risk.

Read more: Analysts See 288% Upside Potential